IL326404A - פירידינים מאוחים לטיפול בסרטן והתוויות נוספות - Google Patents
פירידינים מאוחים לטיפול בסרטן והתוויות נוספותInfo
- Publication number
- IL326404A IL326404A IL326404A IL32640426A IL326404A IL 326404 A IL326404 A IL 326404A IL 326404 A IL326404 A IL 326404A IL 32640426 A IL32640426 A IL 32640426A IL 326404 A IL326404 A IL 326404A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- ring
- independently selected
- sulfur
- nitrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363518242P | 2023-08-08 | 2023-08-08 | |
| US202463666479P | 2024-07-01 | 2024-07-01 | |
| PCT/US2024/041288 WO2025034858A1 (en) | 2023-08-08 | 2024-08-07 | Fused pyridines for the treatment of cancer and other indications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL326404A true IL326404A (he) | 2026-04-01 |
Family
ID=92593266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL326404A IL326404A (he) | 2023-08-08 | 2024-08-07 | פירידינים מאוחים לטיפול בסרטן והתוויות נוספות |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4758146A1 (he) |
| KR (1) | KR20260068141A (he) |
| CN (1) | CN122122158A (he) |
| AU (1) | AU2024320375A1 (he) |
| CL (1) | CL2026000366A1 (he) |
| CO (1) | CO2026001587A2 (he) |
| IL (1) | IL326404A (he) |
| MX (1) | MX2026001519A (he) |
| PE (1) | PE20260853A1 (he) |
| TW (1) | TW202513063A (he) |
| WO (1) | WO2025034858A1 (he) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026026967A1 (zh) * | 2024-08-02 | 2026-02-05 | 劲方医药科技(上海)股份有限公司 | 丙烯酰基类化合物及其用途 |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103501610A (zh) * | 2011-03-09 | 2014-01-08 | 西建阿维拉米斯研究公司 | Pi3激酶抑制剂和其用途 |
| JP7369719B2 (ja) * | 2018-06-12 | 2023-10-26 | アムジエン・インコーポレーテツド | ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法 |
| TW202144349A (zh) * | 2020-04-30 | 2021-12-01 | 大陸商上海科州藥物研發有限公司 | 作為ｋｒａｓ抑制劑的雜環化合物的製備及其應用方法 |
| EP4204412A4 (en) * | 2020-08-26 | 2024-10-09 | InventisBio Co., Ltd. | HETEROARYL COMPOUNDS, PRODUCTION PROCESSES AND USES THEREOF |
| TW202337433A (zh) * | 2022-02-08 | 2023-10-01 | 美商德洛斯股份有限公司 | 用於治療癌症及其他適應症之組成物及方法 |
-
2024
- 2024-08-07 CN CN202480064500.3A patent/CN122122158A/zh active Pending
- 2024-08-07 AU AU2024320375A patent/AU2024320375A1/en active Pending
- 2024-08-07 EP EP24762772.2A patent/EP4758146A1/en active Pending
- 2024-08-07 PE PE2026000239A patent/PE20260853A1/es unknown
- 2024-08-07 KR KR1020267006748A patent/KR20260068141A/ko active Pending
- 2024-08-07 IL IL326404A patent/IL326404A/he unknown
- 2024-08-07 TW TW113129627A patent/TW202513063A/zh unknown
- 2024-08-07 WO PCT/US2024/041288 patent/WO2025034858A1/en not_active Ceased
-
2026
- 2026-02-06 CL CL2026000366A patent/CL2026000366A1/es unknown
- 2026-02-06 MX MX2026001519A patent/MX2026001519A/es unknown
- 2026-02-12 CO CONC2026/0001587A patent/CO2026001587A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2026000366A1 (es) | 2026-06-19 |
| KR20260068141A (ko) | 2026-05-13 |
| WO2025034858A1 (en) | 2025-02-13 |
| CN122122158A (zh) | 2026-05-29 |
| AU2024320375A1 (en) | 2026-02-19 |
| EP4758146A1 (en) | 2026-06-17 |
| PE20260853A1 (es) | 2026-04-17 |
| CO2026001587A2 (es) | 2026-05-07 |
| MX2026001519A (es) | 2026-05-04 |
| TW202513063A (zh) | 2025-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL300147A (he) | תולדות פיפרידין-1-איל-n-פירידין-3-איל-2-אוקסאצטאמיד שימושיות לטיפול בסרטן חסר mtap ו/אוmta מצטבר | |
| IL313807A (he) | נוגדנים קלאודין 18 ושיטות לטיפול בסרטן | |
| IL284326A (he) | מעכבי mat2a אזא-הטרוביציקליים ושיטות לשימוש לטיפול בסרטן | |
| IL327418A (he) | מעכבי ras-pi3k לטיפול בסרטן ובמחלות אימונולוגיות | |
| IL285917A (he) | תכשיר רוקחות המשלב שיטה אימונולוגית וכימותרפית לטיפול בסרטן | |
| IL285647A (he) | חומר ומערכת לטיפול התרפויטי במפרקים | |
| IL277854A (he) | תצמידים של נוגדן ותרופה ושימוש בהם לטיפול בסרטן | |
| ZA202206743B (en) | Therapy for the treatment of cancer | |
| GB202018015D0 (en) | Composition and methods for the treatment of intestinal cancer | |
| EP4048406A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF SOLID AND HEMATOLOGICAL MALIGNANT TUMORS | |
| SMT202500434T1 (it) | Sotorasib per l'uso nel trattamento del cancro | |
| IL304245A (he) | תצמידי פוספוליפיד–פלבגלין ושיטות לשימוש בהם לטיפול ממוקד בסרטן | |
| EP4199961A4 (en) | COMBINATION IMMUNOTHERAPY METHOD FOR TREATING CANCER | |
| IL289251A (he) | שיטות ותכשירים לטיפול בסרטן הלבלב | |
| IL286649A (he) | תולדות קווינולין והשימוש בהן לטיפול בסרטן | |
| IL305780A (he) | שיטות לטיפול בסרטן | |
| IL288178A (he) | טיפול משולב gmci ו– ddri לטיפול בסרטן | |
| ZA202105583B (en) | Methods of diagnosing and treating cervical cancer | |
| GB201918692D0 (en) | Treatment and prognosis of pancreatic cancer | |
| CA3300965A1 (en) | Fused pyridines for the treatment of cancer and other indications | |
| EP4082577A4 (en) | Cancer treatment method and medicine | |
| PL4504202T3 (pl) | Terapie skojarzone do leczenia raka obejmujące GDC-6036 i GDC-0077 | |
| IL304599A (he) | שיטות לטיפול בהפרעת שטף המתפרצת בילדות | |
| IL288433A (he) | שפעול ואימונותרפיה של פרוקספאז-3 לטיפול בסרטן | |
| EP3760614B8 (en) | Chemical inhibitors of id proteins for the treatment of cancer and other diseases |